Industry Breathes Sigh Of Relief Over UK Batch Release Move
One of the key regulatory conundrums thrown up by Brexit has been addressed after the government decided to continue using a list of approved countries to waive drug import testing requirements.
You may also be interested in...
The UK government is consulting on a set of options for batch testing of imported medicines as it seeks to balance patient safety principles with the need to avoid overly burdensome import requirements.
COVID-19 and Brexit have put a great strain on the resources of the EU medicines regulatory system, but the planned review of the EU fee system could produce a system that is more flexible, efficient and better able to respond rapidly to emerging technologies and the needs of health care systems, says EFPIA.
A new committee including representatives of the French pharma industry, health professionals and patients is to lay the groundwork for a longer-term approach to preventing and managing medicine supply chain issues. A separate initiative launched by the prime minister will look at medicines access issues and strengthening the French manufacturing base.